Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors
Birgit Geoerger(Hôpital de la Timone), G. Vassal(Hôpital Necker-Enfants Malades)
Cited by 159
Related Papers
The selective VEGFR1‐3 inhibitor axitinib (AG‐013736) shows antitumor activity in human neuroblastoma xenografts
|International Journal of Cancer|2010|61
Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models
|PLoS ONE|2015|57
EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts
|International Journal of Cancer|2008|56
Dual inhibition using cabozantinib overcomes HGF/MET signaling mediated resistance to pan-VEGFR inhibition in orthotopic and metastatic neuroblastoma tumors
|International Journal of Oncology|2016|44